Lung Carcinoma — Research

Lung Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	273,384	`("Lung Carcinoma"[tiab] OR "Lung Cancer"[tiab] OR "Carcinoma of Lung"[tiab] OR "Carcinoma of the Lung"[tiab] OR "Lung Cancer all types"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	94,693	`("Lung Carcinoma"[tiab] OR "Lung Cancer"[tiab] OR "Carcinoma of Lung"[tiab] OR "Carcinoma of the Lung"[tiab] OR "Lung Cancer all types"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	19,676	`("Lung Carcinoma"[tiab] OR "Lung Cancer"[tiab] OR "Carcinoma of Lung"[tiab] OR "Carcinoma of the Lung"[tiab] OR "Lung Cancer all types"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 19 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (381)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 26–50 of 381 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
· N Engl J Med · 2020 · PMID 32877583 · validated civic_curation pubmed
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
· J Clin Oncol · 2021 · PMID 34339292 · validated civic_curation pubmed
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
· JAMA Oncol · 2021 · PMID 34647988 · validated civic_curation pubmed
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.